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This multicentre double-blind, double-dummy study compared the safety and efficacy of a new combination 
Diskus@ inhaler containing both salmeterol 50 pg and fluticasone propionate 500 pg (Seretide@, GlaxoWellcome, 
France) with the same doses of the two drugs delivered via separate Diskus @ inhalers and with the same dose of 
fluticasone propionate alone. Patients were eligible for study entry if they had received an inhaled corticosteroid 
continuously for 12 weeks prior to run-in, and had received treatment with beclomethasone dipropionate or 
budesonide 150&2000 pg day-’ or fluticasone propionate 75(rlOOO pg day-’ for at least 4 weeks prior to run-in. 
In total, 503 patients receiving inhaled corticosteroids were randomized to 28 weeks’ treatment with either 
salmeterol/fluticasone propionate (SO/500 pg) via a single Diskus@ inhaler (combination) and placebo, or 
salmeterol 50 pg and fluticasone propionate 5OOpg administered via separate Diskus@ inhalers (concurrent), or 
fluticasone propionate 500 pg and placebo. All treatments were administered twice daily, mean morning peak 
expiratory flow rate (PEFR) and asthma symptoms were measured for the first 12 weeks and safety data were 
collected throughout the 28-week study. Over weeks 1 to 12, improvement in adjusted mean morning PEFR was 35 
and 33 1 min-‘, respectively, in the combination and concurrent therapy treatment groups (12 and 10% increase 
from baseline, respectively). The mean difference between treatments was -3 1 min-’ (90% confidence interval 
- 10.4 1 min- ‘) which was within the criteria for clinical equivalence. However, the combination therapy was 
statistically significantly superior to fluticasone propionate alone for mean morning PEFR (P<O.OOl) and other 
measures of lung function, whilst clinical equivalence of the combination and concurrent therapies was observed. 
All three treatments were well tolerated. In addition, there were no differences between the three treatments in either 
the change in serum cortisol or urinary cortisol concentrations, which, for each treatment group, were no 
significantly different from baseline at the end of the treatment period. Thus, the combination of salmeterol and 
fluticasone propionate in a single inhaler is as well tolerated and effective in achieving asthma control in steroid- 
dependent patients as the separate administration of the two drugs, and both combination and concurrent therapy 
are superior to administration of the same dose of corticosteroid alone. 
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Introduction 
Asthma is a chronic inflammatory disease of the airways 
characterized by episodic wheezing, coughing and tightness 
of the chest as a result of airflow obstruction. Treatment 
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therefore consists of the administration of corticosteroids to 
prevent asthma symptoms, decrease airway hyper-respon- 
siveness and reduce the risk of severe excerbations (1,2), 
and bronchodilators to improve diminished lung function 
and reduce the incidence and severity of symptoms by 
reversing bronchoconstriction (3,4). Since no single medi- 
cation is fully effective against both inflammation and 
bronchoconstriction, corticosteroids and bronchodialators 
are frequently administered together. Co-administration of 
corticosteroids and bronchodilators has been subjected to 
national and international review (5-7) and, in an attempt 
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to prevent chronic damage and functional impairment of 
the airways, current guidelines advocate the early introduc- 
tion of corticosteroids once a patient requires short-acting 
bronchodilators more than once daily (8,9). Two relatively 
recent studies established that the addition of salmeterol, a 
long-acting fiz-agonist with a duration of action of at least 
12 h and proven efficacy in the treatment of mild, moderate 
and severe asthma (l&14), to the treatment regimen of 
patients inadequately controlled on inhaled corticosteroids 
alone resulted in a greater improvement in lung function 
and symptom control compared with doubling the dose of 
the corticosteroid (15,16). Recently, another study has 
reported significantly decreased number of severe exacer- 
bations (18) in those patients receiving salmeterol in 
combination with fluticasone propionate compared with 
those receiving double the dose of inhaled corticosteroid. 
Patient compliance decreases with increased complexity 
of treatment (19) and increased frequency of dosing (20); 
therefore, simplifying the treatment regimen by providing a 
single-dose formulation containing both a long-acting 
bronchodilator and cortisteroid in a simple twice-daily 
regimen should lead to improved control of asthma for 
patients needing both treatments. The opportunity was 
therefore taken to combine salmeterol and fluticasone 
propionate, a corticosteroid with high pulmonary resi- 
dence, rapid systemic clearance, oral bioavailability of 
< 1% and proven therapeutic benefit (21-25) in a series of 
three new multiple-dose dry-powder formulations contain- 
ing salmeterol 50 pg with either fluticasone propionate 100, 
250 or 500 pg. These new formulations have been subject to 
stringent double-blind assessment under clinical trial 
conditions in asthma patients with varying degrees of 
severity of reversible airways disease (26,27). 
The aims of this study were to determine if, in patients 
who remained symptomatic on their current corticosteroid 
regimen, the new combined formulation containing salme- 
terol and fluticasone propionate (50/500 pg) in a Disku@ 
inhaler (Seretide@) was superior to the administration of 
fluticasone propionate alone, and if the new combined 
single-dose formulation was therapeutically equivalent to 
the same doses of the bronchodilator and corticosteroid 
administered separately. 
Methods 
The study was conducted under the precepts of Good 
Clinical Practice and conformed to the conditions described 
in the Declaration of Helsinki 1964, modified by the World 
Medical Assembly in Hong Kong 1989. Ethics committee 
approval was obtained by all participating centres and 
patients were only induced in the study if they provided 
written informed consent. 
STUDY DESIGN 
This was a multicentre, randomized, parallel-group study 
involving a ‘Zweek run-in period, a 28-week double-blind, 
double-dummy treatment period, with one of three treat- 
ments administered twice daily, and a 2-week follow-up 
period. Each patient who completed the study was 
scheduled to visit the hospital clinic on eight or nine 
occasions. The follow-up visit was also conducted for 
patients who withdrew, or who were withdrawn, from the 
study before the end of the treatment period, 2 weeks after 
withdrawal. 
PATIENTS 
Male or female patients, aged 212 years, with a documen- 
ted clinical history of reversible airways disease, who had 
received treatment with any inhaled corticosteroid con- 
tinuously for 12 weeks prior to run-in, and received 
treatment with beclomethasone dipropiobate or budesonide 
150&2000 pg day-’ or fluticasone propionate 750-1000 pg 
day- ’ for at least 4 weeks prior to run-in, were considered 
as candidates for the study. Only patients who at the end of 
the 2-week run-in period were symptomatic (symptom score 
22 on at least four of the last seven consecutive days), had a 
mean morning peak expiratory flow rate (PEFR) that was 
> 50% and ~85% of the maximum PEFR 15 min after 
administration of inhaled salbutamol 400 ,ug and a forced 
expiratory volume in 1 set (FEVt) between 50 and 100% of 
its predicted value at the start of treatment, were 
randomized to study treatment. 
STUDY TREATMENTS 
During the run-in period patients continued treatment with 
the same dose of their inhaled steroids. All inhaled short- 
acting bronchodilator formulations taken as ‘rescue’ 
medication for symptomatic relief were replaced by 
salbutamol via either a Diskhale? or a pressurized 
metered-dose inhaler. Patients eligible to commence study 
treatment at the end of the run-in period were randomly 
allocated to treatment with either salmeterol/fluticasone 
propionate (SO/500 pg twice daily) in combination (Sere- 
tide@; combination therapy) via a single Diskus@ inhaler 
and placebo, or salmeterol (50 pg twice daily) via one 
Diskus@ inhaler and fluticasone propionate (500 fig twice 
daily) via a separate Diskus@ inhaler (concurrent therapy), 
or fluticasone propionate (500 pg twice daily) and placebo. 
Regular therapy for asthma, such as anticholinergics, 
theophyllines, sodium cromoglycate, continued unchanged 
throughout the study period. 
ASSESSMENTS 
Patients were assessed in the clinic at the beginning of the 
run-in and treatment periods, at 2, 4, 12, 20 and 28 weeks 
during treatment, and 2 weeks after study treatment was 
stopped. 
Patients entered the following information on a diary 
card each day during the run-in period and the first 12 
weeks of treatment: three morning and evening PEFR 
readings were taken with the highest on each occasion being 
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TABLE 1. Patient demographics and pre-study characteristics 
Salmeterol/fluticasone Salmeterol + fluticasone 
propionate (Combination; propionate (Concurrent; 
50/500 Pi3> 50/500 pi) 
Fluticasone 
propionate (500 pg) 
Number of patients 
Female:male 
Mean (years) age 
Range 
Smoking history 
Current 
Ex-smoker 
Never 
Duration of asthma (years) 
<l 
> 1 to 5 
>5 to 10 
> 10 
History of atopy 
FEVi mean (SEM) (1) 
Absolute 
% predicted 
% reversibility 
Mean (SEM morning PEFR 
during run-in Week 2 (1 min-‘) 
167 171 165 
71:96 85:86 78:87 
46 48 50 
12-78 19-79 12-76 
25 (15%) 27 (16%) 19 (12%) 
63 (38%) 68 (40%) 64 (39%) 
79 (47%) 76 (44%) 82 (50%) 
3 (2%) 3 (2%) 7 (7%) 
40 (24%) 38 (22%) 38 (23%) 
36 (22%) 33 (19%) 31 (19%) 
88 (53%) 97 (57%) 89 (54%) 
87 (52%) 92 (54%) 81 (49%) 
244 (0.06) 2.32 (0.05) 2.33 (0.06) 
73 (1.2) 73 (1.2) 73 (1.4) 
16 (1.0) 18 (1.2) 18 (1.2) 
359 (7.4) 345 (6.6) 351 (8.1) 
FEVt: forced expiratory volume in 1 set; PEFR: peak expiratory flow rate. 
recorded, daytime asthma symptom score (5-point scale 
with 0 indicating no symptoms and 5 indicating severe 
symptoms), night-time asthma symptom score (Cpoint 
scale with 0 indicating no symptoms and 4 indicating 
symptoms preventing and sleep) and the number of doses of 
‘rescue’ salbutamol required during the day and night. All 
PEFR measurements were made prior to taking study 
medication and ‘rescue’ salbutamol. The diary card for 
weeks 13-28 was restricted to the documentation of 
changes in concomitant medication and adverse events. 
The primary efficacy parameter was the mean morning 
PEFR during weeks 1-12. Evening PEFR, symptom-free 
days, symptom-free nights, incidence of days and nights 
when ‘rescue’ salbutamol was not required and the FEV, 
(absolute and predicted) recorded at each clinic visit were 
secondary endpoints. 
Adverse events were monitored throughout the study 
period. Fasting morning (0800 to 1000 h) venous blood 
samples were taken at the start of and after 12 and 28 
weeks’ treatment for the determination of fasting serum 
cortisol levels, standard haematology and biochemistry. 
Twelve-lead ECGs and oropharyngeal examination were 
also conducted at these visits. Twenty-four-hour urine 
collections for measurement of 24-h urinary cortisol 
excretion corrected for creatinine were made in a subset 
of patients (n = 3 18). 
Patients’ compliance with treatment was calculated (as a 
percentage) using the number of doses used (assessed on the 
dose counter on the Diskus@ inhalers) divided by the 
expected use. 
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FIG. 1. Increase in adjusted mean ( f SEM) morning peak 
expiratory flow rate (PEFR) from baseline in asthma 
patients during 12 weeks’ treatment with either salmeterol 
(SLM)/fluticasone propionate (FP) SO/500 pg twice daily 
(combination therapy) or SLM 50 pg twice daily +FP 500 
pg twice daily (concurrent therapy), or FP 500 pg twice 
daily. *P=O.O03; **P<O.OOl combination therapy vs. 
FP. -m- combination therapy (SLMJFP SO/500 pg); 
-a-: concurrent therapy (SLM/FP 50/500 pg); 
-a- FP 500 pg. 
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STATISTICAL ANALYSIS 
All analyses were conducted on an intent-to-treat basis. The 
change in PEFR from baseline (mean PEFR of the second run- 
in week) to week 1, 2, 3, 4, H, 9-12 and overall was 
investigated using Analysis of Covariance, with baseline data as 
a covariate. Confidence intervals were determined using 
unstratified Wilcoxon Rank Sum and treatments were defined 
as equivalent if the 90% confidence interval (CI) for the 
difference in the increase in morning PEFR from run-in 
between any of the three treatments fell within f 15 1 mm’. 
These values were chosen as they have been used and validated 
previously in clinical studies (28) and were considered to 
represent a potential clinically relevant difference. 
Superiority of combination therapy to fluticasone pro- 
pionate alone was based on P-values. Symptom scores and 
the requirement for ‘rescue’ salbutamol were analysed using 
the van Elteren extension to the Wilcoxon Rank Sum test, 
and the change in FEVl from baseline was analysed using 
Analysis of Covariance. The incidences of the most 
common adverse events were compared using the Fisher 
exact test (two-sided). Serum and urinary cortisol concen- 
trations were transformed to a log scale and analysed using 
baseline concentrations as a covariate. 
Results 
A total of 503 patients were randomized to treatment. After 
randomization, 100 patients were withdrawn, comprising 
31 (19%) from the combination therapy group, 28 (16%) 
from the concurrent therapy group and 41 (25%) from the 
fluticasone propionate group. There was no significant 
difference in the number of withdrawals from each 
treatment group. The most common reason for withdrawal 
was an adverse event (see below), other reasons included 
failure to return for follow-up (n = 16), non-compliance 
(n=9) and not fulfilling the entry criteria (n= 1). All 503 
patients were included in the analysis of adverse events. 
There was no statistical difference between these 
TABLE 2. Statistical analyses on improvement in mean morning peak expiratory flow rate (PEFR) (1 min-‘): salmeteroh 
fluticasone propionate 50/500 pg twice daily (combination therapy) versus salmeterol 50 pg twice daily + fluticasone 
propionate 500 ,ug twice daily (concurrent therapy); and salmeterol/fluticasone propionate 50/500 pg twice daily (combination 
therapy) versus fluticasone propionate 500 pg twice daily alone (FP only) 
Weeks Treatment Adjusted mean (SE) 
change from 
baseline 
Mean (SE) 
treatment 
difference” 
Confidence 
intervalb 
P value 
1 Combination 
Concurrent 
FP only 
2 Combination 
Concurrent 
FP only 
3 Combination 
Concurrent 
FP only 
4 Combination 
Concurrent 
FP only 
5-8 Combination 
Concurrent 
FP only 
9-12 Combination 
Concurrent 
FP only 
1-12 Combination 
Concurrent 
FP only 
25 (2.4) 
25 (2.3) 
5 (2.4) 
30 (3.0) 
27 (3.0) 
8 (3.0) 
35 (3.4) 
33 (3.4) 
15 (3.5) 
37 (3.5) 
34 (3.5) 
16 (3.6) 
40 (3.6) 
36 (3.6) 
17 (3.7) 
38 (3.9) 
36 (3.8) 
22 (4.0) 
35 (3.1) 
33 (3.1) 
15 (3.1) 
-1 (3.3) 
-20 (3.3) 
-3 (4.2) 
-22 (4.2) 
-2 (4.7) 
-21 (4.8) 
-4 (4.9) 
-22 (4.9) 
-3 (5.0) 
-23 (5.1) 
-2 (5.4) 
- 16 (5.5) 
-3 (4.3) 
-21 (4.4) 
-6, 4 0.772 
-27. -14 <O.OOl 
-10,4 0.464 
-30, -14 <O.OOl 
- 10, 6 0.633 
-30, -11 <O.OOl 
- 12, 4 
-31, -12 
-12, 5 0.486 
-33. -13 <O,OOl 
- 10, 7 
-27, -5 
-10,4 0.535 
-29, -12 <O,OOl 
0.451 
<O.OOl 
0.771 
0.003 
aNegative treatment difference indicates higher overall value for combination therapy. 
bFor analysis of equivalence of combination versus concurrent therapy 90% confidence intervals are presented; for analysis of 
superiority of combination therapy versus fluticasone propionate alone 95% confidence intervals are presented. 
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withdrawal rates and the three treatment groups were well 
balanced for demographic and baseline characteristics 
(Table 1). 
Mean compliance (mean of medication used expressed as 
a percentage of expected use) during weeks l-28 was 93- 
94% for all treatment groups. 
MEAN MORNING PEFR 
At week 2, the adjusted mean morning PEFR increased by 
30 1 min-’ (10%) in the combination therapy group and by 
27 1 min-’ (9%) in the concurrent therapy group. During 
weeks 9 to 12, increases of 38 (13%) and 36 1 min-’ (11%) 
were reported in the two treatment groups, respectively. In 
comparison, adjusted mean morning PEFR increased by 8 1 
min-’ (3%) at week 2 and by 22 1 min-’ (8%) at weeks 9 to 
12 in patients treated with fluticasone propionate alone 
(Fig. 1). Over the first 12 weeks of treatment the difference 
between the combination and the fluticasone propionate 
alone therapies for the mean increase in morning PEFR 
was -21 1 min-’ which was significantly (P<O.OOl) in 
favour of the combination therapy group (Table 2). The 
mean increase in morning PEFR for the combination 
therapy was also significantly higher (P<O.OOl) than that 
for the fluticasone propionate alone treatment group at all 
other time points during the study period (Table 2) 
During weeks 1-12 the difference between the combina- 
tion and concurrent therapies (concurrent-combination) 
for the mean increase in morning PEFR was -3 1 min-‘, 
with the 90% CI (- 10, 4 1 min-‘) being within the 
equivalence definition of & 15 1 min-’ (Table 2). The 
difference between the combination and concurrent thera- 
pies for change in mean morning PEFR at other time points 
in the study was similar to that reported for weeks 1-12 
(Table 2). 
SECONDARY EFFICACY END-POINTS 
All three treatments improved mean evening PEFR (Table 3) 
and percent predicted mean evening PEFR during weeks 
TABLE 3. Statistical analyses on improvement in mean evening peak expiratory flow rate (PEFR) (1 min-‘): Salmeterol/ 
fluticasone propionate 50/500 pg twice daily (combination therapy) versus salmeterol 50 pg twice daily + fluticasone 
propionate 500 pg twice daily (concurrent therapy); and salmeterol/fluticasone propionate 50/500 pg twice daily (combination 
therapy) versus fluticasone propionate 500 pg twice daily alone (FP only) 
Weeks Treatment Adjusted mean (SE) 
change from 
baseline 
Mean (SE) 
treatment 
difference” 
Confidence 
intervalb 
P value 
1 Combination 24 (2.5) 
Concurrent 20 (2.4) -4 (3.4) -10,2 0.249 
FP only 5 (2.5) - 19 (3.4) -26, -12 <O.OOl 
2 Combination 27 (3.1) 
Concurrent 20 (3.0) -7 (4.2) -14,0 0.102 
FP only 5 (3.1) -22 (4.3) -30, -13 <O.OOl 
3 Combination 31 (3.2) 
Concurrent 24 (3.2) -7 (4.4) -14,o 0.109 
FP only 11 (3.2) -20 (4.5) -28, -11 <O.OOl 
4 Combination 32 (3.4) 
Concurrent 24 (3.3) -9 (4.7) -17, -1 0.060 
FP only 11 (3.4) -21 (4.7) -30, -12 < 0.001 
5-8 Combination 32 (3.5) 
Concurrent 26 (3.4) -6 (4.8) - 14, 2 0.238 
FP only 9 (3.5) -23 (4.9) -32, -13 <O.OOl 
9-12 Combination 31 (3.8) 
Concurrent 26 (3.7) -6 (5.3) - 14, 3 0.270 
FP only 13 (3.9) - 18 (5.4) -29, -8 <O.OOl 
1-12 Combination 29 (3.1) 
Concurrent 23 (3.0) -6 (4.2) -13, 1 0.160 
FP only 9 (3.1) -21 (4.3) -29, -12 <O.OOl 
aNegative treatment difference indicates higher overall value for combination therapy. 
bFor analysis of equivalence of combination versus concurrent therapy 90% confidence intervals are presented; for analysis of 
superiority of combination therapy versus fluticasone propionate alone 95% confidence intervals are presented. 
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1-12 compared with baseline values. At all time points over 
weeks 1-12 the mean increase in evening PEFR for the 
combination and concurrent therapies was significantly 
higher than that for the fluticasone propionate alone 
treatment group (P < 0.02) (Table 3). In addition, through- 
out weeks 1-12 the difference in the increase in mean 
evening PEFR for the combination and concurrent 
therapies remained within the predicted 90% CI (Table 3). 
Combination therapy, concurrent therapy and flutica- 
sone propionate alone all increased the mean percentage 
symptom-free days, symptom-free nights, rescue-free days 
and rescue-free nights over weeks 1-12. Over this period, 
administration of the combination therapy resulted in 10% 
more symptom-free days, 7% more symptom-free nights, 
12% more rescue-free days and 11% more rescue-free 
nights compared with the fluticasone propionate alone 
(Fig. 2). However, there was no significant difference 
between the combination and concurrent therapies for 
any of these measurements over weeks 1-12 (Fig. 2). 
All three treatments resulted in an increase in FEVl 
compared with baseline during the 28-week treatment 
period (12, 7 and 10% increase, respectively, in the 
combination, concurrent and fluticasone propionate alone 
treatment groups (Fig. 3). Combination therapy produced 
the greatest increase in FEVl measured at each clinic visit 
(Fig. 3), but was not significantly different from fluticasone 
propionate alone at week 28 (treatment difference -0.04 1; 
P = 0.454). Similarly, the combination was not significantly 
different from concurrent therapy at week 28 (treatment 
difference -0.1 1; P=O.O61). 
SAFETY 
Overall, all three treatment regimens were well tolerated. 
The incidence of drug-related adverse events was similar for 
the three treatments (combination therapy: 17%; concur- 
rent therapy: 14%; fluticasone propionate alone: 19%). The 
most commonly reported (22% in any group) drug-related 
adverse events are summarized in Table 4. A total of 54 
patients withdrew from therapy because of an adverse event 
(16 patients (10%) treated with combination therapy, 16 
(9%) with concurrent therapy and 22 (13%) with flutica- 
sone propionate). Of these, 32 patients experienced asthma- 
related adverse events. 
No clinically significant changes in laboratory values. 
Physical examinations or vital signs were observed in any of 
the three treatment groups. There were no significant 
differences in change in serum cortisol levels or 24-h urinary 
cortisol (corrected for creatinine) between the three treat- 
ment groups, nor were these parameters significantly 
different between baseline and the end of 28 weeks’ therapy 
for any of the treatment groups (Table 5). 
Discussion 
International guidelines for the treatment of asthma 
recommend co-administration of long-acting bronchodila- 
tors and corticosteroids in patients whose asthma is not 
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FIG. 2. Mean percentage symptom-free days and nights, 
and rescue medication-free days and nights over weeks I- 
12 of treatment with either salmeterol (SLM)/fluticasone 
propionate (FP) SO/500 1.18 twice daily (combination 
therapy) or SLM 50 pg twice daily +FP 500 fig twice daily 
(concurrent therapy), or FP 500 pg twice daily. n : 
combination therapy (SLM/FP SO/500 pg); H: concurrent 
therapy (SLM/FP SO/500 /*g); q : FP 500 pg. 
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FIG. 3. Increase in mean (+ SEM) FEVi values in adults 
with asthma during 28 weeks’ treatment with either 
salmeterol (SLM)/fluticasone propionate (FP) SO/500 pg 
twice daily (combination therapy) or SLM 50 pg twice 
daily +FP 200 pg twice daily (concurrent therapy), or FP 
500 pg twice daily. -m-: combination therapy (SLM/FP 
SO/500 pg); -O-: concurrent therapy (SLM/FP 50/500 
pg); -A-: FP 500 pg. 
controlled by inhaled corticosteroids (8,9). A recent report 
by a panel of experts also concluded that long-acting /I- 
agonist therapy should be accompanied by anti-inflamma- 
tory medication (29). In the U.K. in 1994, steroids were co- 
prescribed with sahneterol in 77% of all prescriptions 
containing salmeterol, in accordance with studies demon- 
strating the therapeutic benefits of combining salmeterol 
with inhaled corticosteroids under double-blind conditions 
(1518). Furthermore, long-term regular administration of 
salmeterol does not lead to deterioration of asthma (12). 
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TABLE 4. Number (%) of patients experiencing the most commonly reported (22% in any group) drug-related adverse events 
during 28 weeks’ treatment with either salmeterol/fluticasone propionate SO/500 pg twice daily (combination therapy), 
salmeterol 50 pg twice daily + fluticasone propionate 500 pg twice daily (concurrent therapy), or fluticasone propionate 500 
pg twice daily 
Combination Concurrent Fluticasone 
therapy therapy propionate 
No. patients 167 171 165 
No. patients (%) with drug-related adverse event 28 (17%) 24 (14%) 32 (19%) 
Asthma 4 (2%) 6 (4%) 3 (2%) 
Breathing disorders 5 (3%) 1 (<l%) 4 (2%) 
Cough 2 (1%) 0 5 (3%) 
Hoarseness/dysphonia 4 (2%) 2 (1%) 6 (4%) 
Throat irritation 2 (1%) 2 (1%) 5 (3%) 
Headaches 3 (2%) 1 (<lo/,) 2 (1%) 
TABLE 5. Effects of 28 weeks’ treatment with either salmeterol/flucasone propionate SO/500 pg twice daily (combination 
therapy), salmeterol 50 pg twice daily + fluticasone propionate 500 pg twice daily (concurrent therapy), or fluticasone 
propionate 500 pg twice daily on serum cortisol and urinary cortisol levels 
Combination therapy Concurrent therapy Fluticasone propionate 
Geometric Geometric Geometric Geometric Geometric Geometric 
mean mean mean mean mean mean 
(coefficient of ratioa (coefficient of ratioa (coefficient of ratioa 
variation) variation) variation) 
Serum cortisol (nmol 1-l) 
Week 0 
Week 12 
Week 28 
Urinary cortisol (corrected for creatinine) 
Week 0 
Week 12 
Week 28 
354 (0.72) 360 (0.68) 352 (0.65) 
391 (0.59) 1.13 384 (0.58) 1.11 349 (0.77) 1.02 
352 (0.67) 1.02 347 (0.80) 1.01 344 (0.65) 0.97 
20 (0.53) 19 (0.62) ,19 (0.62) 
19 (0.69) 0.99 20 (0.68) 1.06 19 (0.66) 0.99 
20 (0.51) 0.97 19 (0.48) 0.98 17 (0.42) 0.90 
“Ratio: Value at Week 12 or 28/value at Week 0. 
Co-administration of steroids and bronchodilators there- 
fore appear to be beneficial in current clinical practice. The 
results of this study demonstrate that the combination of 
salmeterol 50 pg and fluticasone propionate 500 pg in a 
single Diskus @ inhaler is clinically superior to the same 
dose of fluticasone propionate administered alone and 
clinically equivalent to the separate administration of the 
two drugs. This is in agreement with earlier studies that 
showed the addition of salmeterol to ongoing corticosteroid 
therapy to be clinically superior to doubling the dose of 
inhaled corticosteroid (15-l 8). Significant improvements in 
lung function were observed in all treatment groups. 
Significantly greater improvements were observed in those 
patients receiving salmeterol and fluticasone propionate 
either via a single Diskus@ inhaler or via separate inhalers. 
Considerable increases in the percentage of symptom-free 
days and nights, and rescue medication-free days and nights 
were observed in all treatment groups, again with the 
increase being greater in those patients receiving both 
salmeterol and fluticasone propionate. 
All three treatment regimens were well tolerated through- 
out the 28-week study, with the incidences and types of 
drug-related adverse events being similar in all treatment 
groups. Furthermore, there was no difference between the 
three treatments in the charge in serum cortisol or urinary 
cortisol concentrations, which, for each treatment group, 
were not significantly different from baseline after 28 weeks’ 
treatment. 
Compliance was high in all treatment groups over both 
the 1Zweek efficacy period and the 28-week safety period. 
However, compliance with regular asthma therapy is 
variable and is known to decrease with increased 
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complexity of treatment (19) and increased frequency of 
dosing (20). By combining salmeterol and fluticasone 
propionate in a single inhaler, and thus simplifying therapy, 
compliance in clinical practice will be facilitated and it is 
hoped that asthma control will improve. The combination 
of the two drugs in a single inhaler should increase 
convenience for the patient. 
In conclusion, the combination of salmeterol and 
fluticasone propionate in a single inhaler for controlling 
asthma in steroid-dependent patients is more effective than 
the same dose of fluticasone propionate administered alone 
and is as effective as the separate administration of the two 
drugs. The combination product is as safe and well 
tolerated as the separate administration of the two drugs. 
This novel combination product is simple, easy to use, 
convenient and effective in the treatment of asthma and its 
use may result in increased patient compliance in clinical 
practice leading to improved asthma control. 
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